论文部分内容阅读
目的:观察参附注射液对乳腺癌患者外周血细胞免疫功能的影响。方法:应用流式细胞术对76例晚期乳腺癌患者外周血T淋巴细胞(CD4、CD8、CD4/CD8)及自然杀伤细胞(NK细胞)活性进行检测,比较化疗的同时使用胸腺肽α1、胸腺肽α1+参附后的差异。将76例乳腺癌患者随机分为三组,一组未使用药物处理;一组接受胸腺肽α1治疗;一组接受参附+胸腺肽α1治疗。结果:化疗后空白对照组CD4、CD8、CD4/CD8、NK细胞值与化疗前比均降低(P<0.05);化疗后胸腺肽组α1及参附+胸腺肽α1组CD4、CD8、CD4/CD8、NK细胞值与化疗前比均明显升高(P<0.05),且参附+胸腺肽α1组升高较胸腺肽α1组明显(P<0.05)。结论:可提高晚期乳腺癌患者外周血细胞免疫功能的作用。
Objective: To observe the effect of Shenfu injection on cellular immune function in peripheral blood of patients with breast cancer. Methods: The activity of T lymphocytes (CD4, CD8, CD4 / CD8) and natural killer cells (NK cells) in peripheral blood of 76 patients with advanced breast cancer were detected by flow cytometry. Thymosin α1, After attachment to the difference. 76 patients with breast cancer were randomly divided into three groups, one without drug treatment; one group received thymosin α1 treatment; one group received treatment of Shenfu + thymosin α1. Results: The levels of CD4, CD8, CD4 / CD8, NK cells in the blank control group after chemotherapy were significantly lower than those before chemotherapy (P <0.05) The NK cell level was significantly higher than that before chemotherapy (P <0.05), and the level of NK cells was significantly higher than that of the thymosin α1 group (P <0.05). Conclusion: It can improve the immune function of peripheral blood cells in patients with advanced breast cancer.